logo

Adaptive Biotechnologies (ADPT)



Trade ADPT now with
  Date
  Headline
8/10/2020 4:15:17 PM Adaptive Biotechnologies Q2 Loss/Shr $0.26 Vs Loss $1.23 Last Year
8/4/2020 9:49:50 AM Adaptive Biotechnologies Launches ImmunoSEQ T-MAP COVID, T Cell Monitoring Tool For SARS-CoV-2
7/28/2020 8:42:55 PM Adaptive Launches National Clinical Trial To Develop Novel T-Cell Based Diagnostic For Lyme Disease
6/11/2020 9:05:09 AM Adaptive Biotechnologies, Microsoft Launch ImmuneCODE Database To Share Populationwide Immune Response To COVID-19 Virus
5/12/2020 4:09:51 PM Adaptive Biotechnologies Q1 Loss/share $0.25 Vs. Loss $1.45 Year Ago
4/7/2020 9:17:37 PM Amgen, Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration
4/2/2020 9:02:34 AM Amgen And Adaptive Biotechnologies Announce Collaboration To Develop Therapeutic To Prevent Or Treat COVID-19
2/26/2020 4:21:55 PM Adaptive Biotechnologies Q4 Loss/share $0.17 Vs. Loss $1.03 Year Ago
1/13/2020 7:44:24 AM Adaptive Biotechnologies Announces Multi-year, Global Diagnostic Agreement With Genentech
6/22/2019 11:57:09 PM Biotech IPOs For The Week Ahead
5/31/2016 4:18:25 PM Adeptus Health Inc. (ADPT) Has Raised Its 2016 EPS Estimate To 2.55 - 2.65 From 2.50 - 2.60
5/31/2016 4:17:59 PM Adeptus Health Inc. (ADPT) Has Raised Its 2016 Revenue Estimate To $640 - $670 Mln From $635 - $665 Mln
10/23/2015 9:03:27 AM RBC Capital Markets Is Raising Adeptus Health Inc. (ADPT) FY17 Rev. Estimate To 744.3 M From 731.6 M
10/23/2015 9:03:14 AM RBC Capital Markets Is Increasing Adeptus Health Inc. (ADPT) FY16 Rev. Estimate To 575.6 M From 565.8 M
10/23/2015 9:02:58 AM RBC Capital Markets Is Increasing Adeptus Health Inc. (ADPT) FY15 Rev. Estimate To 408.6 M From 405.0 M